Harpoon Therapeutics
Stock Forecast, Prediction & Price Target
Harpoon Therapeutics Financial Estimates
Harpoon Therapeutics Revenue Estimates
Harpoon Therapeutics EBITDA Estimates
Harpoon Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2020 | 12/31/2021 | 12/31/2022 | 12/31/2025 | |||
Revenue
% change YoY
| $17.44M N/A | $23.65M 35.59% | $31.91M 34.92% | Avg: $18.81M Low: $18.81M High: $18.81M avg. -41.05% | |||
Net Income
% change YoY
| $-46.37M N/A | $-166.43M -258.87% | $-67.13M 59.66% | Avg: $-9.25M Low: $-9.25M High: $-9.25M avg. 86.21% | |||
EBITDA
% change YoY
| $-49.24M N/A | $-14.65M 70.24% | $-68.32M -366.28% | Avg: $-17.38M Low: $-17.38M High: $-17.38M avg. 74.56% | |||
EPS
% change YoY
| -$18.52 N/A | -$51.57 -178.45% | -$20.24 60.75% | Avg: -$2.79 Low: -$2.79 High: -$2.79 avg. 86.21% | |||
Operating Expenses
% change YoY
| $68.77M N/A | $90.45M 31.51% | $100.24M 10.82% | Avg: $28.05M Low: $28.05M High: $28.05M avg. -72.01% | |||
FAQ
What is Harpoon Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 86.21% in 2025-2025.
We have gathered data from 3 analysts. Their low estimate is -9.25M, average is -9.25M and high is -9.25M.
What is Harpoon Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of -41.05% in 2025-2025.
We have gathered data from 1 analysts. Their low revenue estimate is $18.81M, average is $18.81M and high is $18.81M.
What is Harpoon Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 86.21% in 2025-2025.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$2.79, average is -$2.79 and high is $-2.78.
What is the best performing analyst?
In the last twelve months analysts have been covering Harpoon Therapeutics stock. The most successful analyst is Joseph Catanzaro whose win rate is 50%. He has correctly predicted 1/2 price targets.